Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Nucleocytoplasmic Transport Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RAN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RAN Recombinant Protein (Wild Type & GTP/GDP-Loaded States) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for nucleotide exchange and effector binding assays. |
View RAN Products |
| Mutant Proteins | RAN Mutant Proteins (Q69L Constitutively Active / T24N Dominant Negative) High purity (>95%), Sequence Verified. For specificity and pathway blocking validation. |
View RAN Products |
| Gene Delivery | RAN Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for target overexpression and phenotypic screening. |
View RAN Products |
| Benchmark Ab | Anti-RAN Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View RAN Products |
| Validator | RAN siRNA Set For knockdown verification and target validation in cell-based functional assays. |
View RAN Products |
| Related Target A | XPO1 (Exportin-1) Major nuclear export receptor interacting directly with the RAN-GTP gradient; clinical validation in hematological malignancies. |
View XPO1 Products |
| Related Target B | KPNB1 (Importin beta-1) Nuclear import receptor dependent on RAN GTPase activity for cargo release; key oncology co-target. |
View KPNB1 Products |
| Related Target C | RCC1 (Regulator of Chromosome Condensation 1) The primary guanine nucleotide exchange factor (GEF) for RAN; critical control point for RAN activation. |
View RCC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nucleotide-state dependent binding (GTP vs. GDP conformation) | State-specific RAN proteins pre-loaded with GTP/GDP analogs available with >95% purity. |
| Off-target screening against other small GTPases (Ras, Rab, Rho) | Homolog panel of small GTPase family proteins strictly verified by mass spectrometry. |
| Lack of positive control antibodies | Sequence-defined recombinant benchmark antibodies included for assay standardization. |
| False positives in phenotypic assays | Sequence-verified siRNA sets included for target-specific knockdown controls. |
Live RAN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RAN therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapies to targeted nucleocytoplasmic transport (NCT) inhibitors. As first-generation NCT therapies (such as XPO1 inhibitors) reach the clinic, the next wave of R&D is targeting RAN directly or through its critical exchange factors like RCC1. Because RAN overexpression is a well-documented driver of aggressive metastatic phenotypes and multi-drug resistance in solid tumors, disrupting the RAN-GTP gradient has emerged as a high-value oncology strategy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Collaborations, Biotech Startups | Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), Glioblastoma | Nucleotide Exchange Assay (Need nucleotide-specific RAN WT and Mutants) |
| Protein-Protein Interaction (PPI) Blockers | Oncology-focused Biopharma | Chemoresistant Solid Tumors, Hematological Malignancies | Binding Affinity & Kinetics (Need high-purity RAN and RCC1/RanBP1 proteins) |
| RNA Therapeutics (siRNA/ASO) | RNAi Specialist Biotechs | Advanced Solid Tumors | In vitro Knockdown Validation (Need sequence-specific RAN siRNA & qPCR controls) |